758-759 / 2437
Targeted therapy
•
Bevacizumab
=> probably no need to cross the BBB
•
EGFR inhibitors (erlotinib, gefitinib…)
=> only in patients with sensitizing EGFR mutation
•
ALK inhibitors (crizotinib, ceritinib…)
=> only in patients with EML4-ALK translocation